2012年美国干细胞治疗应用大幅上升

botizhou

Dramatic Rise in Stem Cell Therapy Use in 2012
) T5 h8 t1 A$ @ Stem Cell Company Executives, Scientists, Investors and Physicians will present data Feb. 19，2013 at the 8th Annual New York Stem Cell Summit in New York City+ ^/ b+ L! ], Z; P+ L
PR Newswire (http://s.tt/1uSNJ)& ]+ Y% J0 U" P, v

1 }; }* S! V" p( U! ZPHILADELPHIA, Nov. 26, 2012 /PRNewswire/ -- RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."5 ^3 ?% d' J/ s4 N
Mr. Young's revised forecast of stem cell commercialization revenues for 2013-2020 will be presented at the February meeting in New York.
# I- r/ ~7 s6 k4 ?7 v& zThe companies, scientists and physicians that are at the forefront of this remarkable increase in stem cell therapeutic use will be presenting at the 8th Annual New York Stem Cell Summit. Listed below is the preliminary lineup of presenters for the 8th Annual Stem Cell Summit. * }1 B+ }3 N; L
The Stem Cell Summit, an intensive one-day event, allows attendees to learn about the latest developments in the stem cell marketplace, evaluate the groundbreaking stem cell products physicians are using today, and discover the growing market potential in terms of revenues. For 2013, the Summit will feature 30+ presenters, a research review and debate session, and a special track on expanding the range of stem cell therapies./ K3 Q( M' a1 |! {  K6 O
The 8th Annual Stem Cell Summit will take place on Feb. 19, 2013, at Bridgewaters in the heart of New York City's historic South Street Seaport. The preliminary roster of companies featured will include representatives from 2012 presenters and new 2013 presenters.
, P  C9 J* T  o7 m" V9 N: i  E
! }: j5 K7 z  k5 e( f$ X. I* CAastrom Biosciences, Inc.8 H9 h+ K% l  E, Q
Advanced Cell Technology; u( b' ]% D  m
Aldagen, Inc.
$ k  {8 T6 L& ]; u2 nAllCells, LLC.5 I3 t! h2 m3 F6 U; q5 e0 ~7 z
Aruna Biomedical, Inc.
/ Q1 P% o, E. X- C( K& |Athersys, Inc.
" O2 k- N6 V1 C) ABioheart Inc.
1 B" i' y+ l& L$ z6 c- h1 bBioLife Solutions: i" l$ M, P9 Y% B8 T) J) j/ g- J, u
BioTime Inc./Embryome Sciences, Inc.
: S5 p  F7 G1 s1 x& A+ y! EBrainstorm Cell Therapeutics0 ]4 t. N+ J8 E* j/ g  ]7 [/ o+ E
Case Western Reserve University
1 p7 X, T* X2 J* m* tCellCyte Genetics Corp.
. {4 ^( h  u9 lCelgene Corporation' S+ m8 O8 n3 j, r3 `- A
Celtigen Therapeutics
5 m/ M4 |9 `- B4 ICord Blood America, Inc. (CBAI.OB); h5 k2 Y  c9 j
Core Dynamics Ltd.
5 N' t) @& }3 y/ c( [, MCytori Therapeutics, Inc.$ @/ G# B9 u! o0 c
Gamida Cell Ltd.
" @  g- X+ h( S8 p6 SGarnet BioTherapeutics, Inc. + n9 W+ D6 c! j: }" O. B
Histogen Inc
7 r" ^- c$ X8 R. _7 d$ G) gINCELL Corporation LLC+ K- p2 M+ m, h% b6 Y" f2 t4 j; U
International Stem Cell Corporation
# X9 y  u% n5 [) A. G/ [  J! FLifenet Health 8 @3 `; N+ a+ k: p2 E% |7 H8 k9 t
Lonza Group Ltd.                , {7 m+ D  x% M/ {, \
Medistem Inc.0 Z8 l1 t9 j, N
Mesoblast Limited
3 e2 |8 A* E  i$ k1 y8 l/ RMultiCell Technologies [MCET]
0 ], z8 ]( e, g1 KNeostem, Inc.
$ @& E& Q' h, \$ U1 _0 |Neuralstem
, B" i: n8 p" D5 Q5 R# u0 ROpexa Therapeutics, Inc.
  k- U/ f" E6 G  DOsiris Therapeutics, Inc.
! Y7 a' p/ g1 A3 ]9 ]Parcell Labs% V& Z# k1 |/ s: l! P( t( ^& j
Pathfinder Cell Therapy
$ [2 m# \8 ]2 ^7 L! p) Z( [Pervasis Therapeutics, Inc.8 }; F0 q, x/ h9 Y
Pluristem Therapeutics, Inc.
7 K. Q! g/ Q/ Q' iProchon Biotech, Ltd." A  N9 f, ^# W0 _; c- w
Progenitor Cell Therapy, LLC- j; P& |& {% ?: r
Stem Cell Innovations( ^% S9 U5 `$ \" _: }1 Z# m3 Z8 e
Stem Cell Therapeutics (SCTPF)  @3 t0 m6 u2 R" w3 H* A, N  p
StemCells Inc.
+ ~$ j1 k9 N6 s2 A" cTiGenix NV6 u3 f" ~/ ^# L* a3 h' B
Tissue Genesis, Inc.
( s) J- s1 c5 N! \# yTxCell) r% B" ?; F) S2 k
Vet-Stem, Inc.
  a! X" p& W8 P5 YViaCyte2 \$ r0 n2 d" Y) L/ ~& U& K7 Z
WuXi AppTec0 c$ C. E2 _8 G$ v9 }6 a- i
) u; q" f1 M, n+ D# D; _% }4 U
In addition to the company and product overviews, Robin Young, president of RRY Publications and the organizer of the annual Stem Cell Summit, will deliver his updated 10-year market forecast for the industry. / ]7 L! x2 o: O' K9 s$ D7 M! q" P

junxie

这对中国干细胞发展是推动

elaine_tang

干细胞的研究者们加油哇，看到希望了

JOEL

回复 botizhou 的帖子6 ]# Z1 a5 z3 o3 A  O$ P' g

+ K$ ]: C9 E9 E5 {% a  I# Q9 v7 t. R9 H- m" P9 O0 }
' o- S  V& d% C" J7 C/ k8 f- v* T* o
“......Virtually all of the increases we're seeing are for adult stem cell therapies and, in particular, the use by physicians of both allograft and autologous stem cell products. It would not be an exaggeration to call this unexpected and remarkable growth."
* y* M: |7 _# ~3 _% s( k
2 L: N- J3 A: C8 L1 b! dThanks to Botichou for the sharing of this article.
# B  ^6 R5 Y* ?- s
2 q9 L- Y$ q& L: U8 q! _& D請特别重申本文報導之核心，在美國顕著上昇的 SCR 和應用， 依然是聚焦在---ASCR 和 PiPS 的硏發和應用； 爾绝非 "IVF-hESCR Assembly-Line" (制造---毁灭流水线式人类胚胎的干细胞研究)---那种短視狭隘狂熱的科學主義，無視人类生命倫理價值， 犹如纳粹創始的， 臭名昭著的所謂优生學---蛮野行徑！！！6 G/ O2 r+ F! U/ ]6 k9 M# G% x: F
9 b  H1 U# Z6 ?  Z